SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 11.62% growth in the revenue at Rs. 68.09 millions for the quarter ended March 2026 as compared to Rs. 61.00 millions during the year-ago period.The Net Loss for the quarter ended March 2026 is Rs. -23.40 millions as compared to Net Loss of Rs. -82.68 millions of corresponding quarter ended March 2025 Operating profit Margin for the quarter ended March 2026 improved to 11.36% as compared to -50.69% of corresponding quarter ended March 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 68.09 61.00 11.62 237.32 433.12 -45.21 237.32 433.12 -45.21
Other Income 20.04 3.38 492.90 20.26 7.09 185.75 20.26 7.09 185.75
PBIDT 11.36 -50.69 -122.41 -34.23 -143.21 -76.10 -34.23 -143.21 -76.10
Interest 19.10 16.15 18.27 70.86 59.14 19.82 70.86 59.14 19.82
PBDT -7.74 -66.84 -88.42 -105.09 -202.35 -48.07 -105.09 -202.35 -48.07
Depreciation 15.66 15.69 -0.19 64.23 66.89 -3.98 64.23 66.89 -3.98
PBT -23.40 -82.53 -71.65 -169.32 -269.24 -37.11 -169.32 -269.24 -37.11
TAX 0.00 0.15 0.00 0.00 0.15 0.00 0.00 0.15 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -23.40 -82.68 -71.70 -169.32 -269.39 -37.15 -169.32 -269.39 -37.15
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) 16.68 -83.10 -120.08 -14.42 -33.06 -56.38 -14.42 -33.06 -56.38

Krebs Biochem.&Inds Share Price

65.00 1.30 (2.04%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×